📣 ESTRO 2026 Pre-Meeting Webinars Get ready for #ESTRO26 with two online pre-meeting webinars ahead of the congress in Stockholm (15–19 May 2026). Cases will be discussed — we can’t wait to engage with you! 🔗 Info & registration: bit.ly/4pAM9PH #PMCwebinars #ESTRO26

The #NeuroRNA team really enjoyed attending the #CancerNeuroscience meeting organised by the #EACR this week in #Bilbao. Josune Alonso and Ane Rubio presented their projects in #RNA misprocessing in #GBM @biogipuzkoa.bsky.social @helloeacr.bsky.social

Congrats to Ethan Ludmir and Chad Tang for their publication selected for recognition as part of @mdanderson.bsky.social Excellence in Science Award. #radonc #endcancer ascopubs.org/doi/10.1200/...

Interested in #reirradiation heading to the first full day of #ESTRO25? Why not follow our 🔹Reirradiation Journey🔹 through the conference programme! Find it in the programme filter options - or below #radonc #medphys

✨We're thrilled to be taking part in #ESTRO25 in Vienna! EORTC researchers will be presenting cutting-edge findings in #RadiationOncology, a cornerstone of our scientific strategy. Find out more: www.eortc.org/blog/2025/05... @estroradiotherapy.bsky.social #CancerResearch

What a start , @mguckenberger.bsky.social with an emotional and inspiring talk at the opening Ceremony, Pascal Uffer delivered more than a talk ; if cancer were a start up. #ESTRO25 #radonc #radiotherapy

The phase III NRG/RTOG 0920 trial explored adding cetuximab to postoperative radiotherapy (RT) in 577 patients with resected intermediate-risk SCCHN. 📊 Key Findings @ascocancer.bsky.social #JCO #Onco404 #Cancer #Kanser #Oncology #HeadAndNeckCancer #RadiationTherapy #Cetuximab #ClinicalTrials #HPV

In the KEYNOTE-689 trial, neoadjuvant pembrolizumab delivered a game-changing: ✅ Event-Free Survival (EFS) Hazard Ratio: 0.73 (95% CI: 0.58–0.92) ✅ Median EFS: 51.8 months vs. 30.4 months No clear benefit seen in the hypopharynx subgroup #HNSCC #Radonc #Immunotherapy #CancerResearch

durvalumab plus tremelimumab with concurrent radiotherapy : 81% CR #radonc #GU

Treatment of Pleural Mesothelioma: ASCO Guideline Update https://buff.ly/3WrRMUm The ASCO guidelines for pleural #mesothelioma (PM) provide evidence-based recommendations for physicians on managing this condition. #LungCancer

bevacizumab, a VEGF inhibitor, in patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma. https://buff.ly/40qpx9W

Nivolumab Improves DFS in High-Risk Head & Neck SCC The Phase 3 NIVOPOSTOP trial (680 patients) showed that adding nivolumab to standard post-op CRT significantly improved DFS in resected LA-SCCHN with high relapse risk. A trend toward better OS was observed, pending final analysis.

Our latest study, "Pulmonary Stereotactic Body Radiotherapy (SBRT) of Oligometastatic Head-and-Neck Squamous Cell Carcinoma (HNSCC): A Multicenter Retrospective Study", is now available in the @ijrobp.bsky.social www.redjournal.org/article/S036...

In Greenland, as we speak.

Todas is HCC day! - RTOG 1112 - HCC unsuitable for or refractory to local-regional Tx (n=177) - SBRT & Sorafenib vs Sorafenib - After adjustment for stratification factors, improved OS after SBRT (HR 0.72) - Median PFS improved from 5.5 to 9.2 mo (HR 0.55) jamanetwork.com/journals/jam...

The RACE-GB trial results are here! FIRST randomized controlled trial investigating radiotherapy (RT) in gallbladder cancer. In a cohort of 135 patients the addition of RT after 4 cycles of chemotherapy (compared to observation) extended overall survival (OS) from 4 months to 10 months.@RadOnc

#RadOnc starter pack loading! Please let me know if you would like to be added. go.bsky.app/TbynCkm #oncsky #bcsm #gyncsm #hncsm

Radiation Oncology is characterized by rapid innovation Dissemination & implementation are important aspects to bring this progress to our cancer patients in daily practice Well written review by Erin Gillespie and colleagues 👇 www.redjournal.org/article/S036...